Community Research Federal Ministry of Education and Research German EU Presidency 2007 ESFRI DESY

Challenge 3c: Infrastructures and users

M. Altarelli, European XFEL Project team leader
User policy at the XFEL as a European Research Infrastructure
The European X-ray Free-Electron Laser was conceived as a user facility, following the model of ESRF in Grenoble (with adaptations technically motivated by the differences between synchrotron and FEL experiments). This approach is visible in technical choices, such as the multitude of beamlines and experimental stations, simultaneously accommodating different group of users, thanks to the high repetition rate of a superconducting FEL. The aim of a close relationship with the users is also reflected in an FP7 proposal for the Preparation Phase, presently under processing, which foresees a large investment in the organisation of users’
workshops and meetings.

M. Hrabé de Angelis, Director of the German Mouse Clinic, GSF National Research Center for Environment and Health
Evaluation of performance: Infrafrontier - A user driven distributed infrastructure for modelling human disease
Life Sciences in the field of medicine use the mouse as a model system to understand the molecular basis of health and disease in humans. An essential task in the 21st century will be the functional analysis of mouse models for every gene in the mammalian genome. The major bottlenecks will be proper characterisation (Mouse Clinics), archiving, and dissemination to research laboratories. The current capacities, governance structures and funding strategies will not be able to serve the upcoming urgent needs. It is now imperative to organise and establish an efficient distributed infrastructure for the phenotyping, archiving, and distribution of mouse models on a well organised Pan-European level. Infrafrontier will guarantee accessibility and will
be essential for the exploitation of mouse models for human diseases. It will give Europe a leading position in the worldwide competition in resources and knowledge for medically relevant mouse models by providing a user-driven platform.

S. Muscella, Head of Communication & International Co-operation Division, Metaware SpA
Fostering Users’ Adoption of e‑Infrastructure
The presentation will focus on the needs and challenges of users in using e‑Infrastructures from various vertical markets. It does so whilst considering the track records of early adopters and vendors as commercial enterprises introduce global e‑Infrastructure technologies to their core enterprise IT operations. It is fundamental to understand the needs of European users. A principal concern is that they do not wish to deploy proprietary technology, whilst another group of users is simply unaware of the potential benefits of e‑Infrastructures to their businesses, and to wider European productivity.
It is increasingly evident that enterprises will only collaborate in building cross-organisation infrastructure components once they are confident that these represent real commercial opportunities for them. The presentation will demonstrate how new user groups can benefit from using e‑Infrastructures in the long term. Specific reference to developments of current e‑Infrastructures achieved in India and in Latin America will be made.

O. Wiestler, Director of the Deutsches KrebsForschungsZentrum (DKFZ)
Translational Research Infrastructure
Translational biomedical research marks the critical link between laboratory work in biology and medicine and the translation of results into clinical diagnosis and treatment.
At present, there is a striking gap between basic science and clinical medicine. Thus, the implementation of a large infrastructure for translational research that links both clinical and basic scientists as well as strong industrial partners is of key importance.
As a first step to achieve international leadership, we propose an EATRIS consortium built on an initial core of advanced European research centres with a strong translational mission in diseases that are of major importance to the European population. They will have the primary goal of significantly promoting the transfer of research findings into clinical practice.
The centres will closely interact and will serve as a nucleus for the European Advanced Translational Research Infrastructure. Additional dedicated centres are expected to join. This strategy is needed to secure the European Union’s position as world leaders in the field of translational medical research. It will also considerably strengthen the economic potential of health-care markets in Europe, with a strong emphasis on “tech trans” from research to industry.

 

 
top